Skip to main content
OpenTrials
Completed

NCT Number: NCT06162507

Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis

This is a multi-center, single arm, open-label study to evaluate safety in children patients with moderate-to severe atopic dermatis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 year–11 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Beijing Children's Hospital Capital Medical University

Beijing, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • With atopic dermatis.
  • Voluntarily sign the informed consent form.

Exclusion criteria

  • Any major surgery planned during the research period.
  • With intestinal parasitic infection within the first 6 months of screening.
  • With any previous malignant tumors prior to screening.
  • With any circumstance that is not suitable to participate in this study.

Treatment and study plan

CM310

Biological

CM310 injection

Primary outcomes

  1. Adverse events

    Time frame: up to week 16

    Incidence of adverse events.

Sponsors and collaborators

Lead sponsor

Keymed Biosciences Co.Ltd

Industry

Registry information

Official study title

A Multicenter, Single-arm, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetics of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatitis

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Dec 8, 2023
Registry last updated
Oct 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.